Toggle Main Menu Toggle Search

Open Access padlockePrints

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: The LITMUS Imaging Study

Lookup NU author(s): Kristy Wonders, Dr Dina Tiniakos, Professor Quentin AnsteeORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Publication metadata

Author(s): Pavlides M, Vali Y, Mozes FE, Wonders K, Akhtar S, Hockings PD, Shumbayawonda E, Pepin K, Fernandez-Lizaranzu I, Leeming DJ, Cobbold J, Allison M, Aithal GP, Romero-Gomez M, Aller R, Pericas JM, Boursier J, Petta S, Schattenberg JM, Ekstedt M, Berzigotti A, Yki-Järvinen H, Martic M, Tuthill T, Brass C, Kalutkiewicz M, Banerjee R, Ehman RL, Schneider MJ, Tiniakos D, Karsdal M, Magnanensi J, Fournier-Poizat C, Ratziu V, Yunis C, Bugianesi E, Harrison S, LITMUS Consortium Investigators, Bossuyt PM, Anstee QM

Publication type: Article

Publication status: Published

Journal: Nature Medicine

Year: 2026

Pages: Epub ahead of print

Online publication date: 24/07/2026

Acceptance date: 29/05/2026

Date deposited: 01/06/2026

ISSN (print): 1078-8956

ISSN (electronic): 1546-170X

Publisher: Nature Publishing Group

URL: https://doi.org/10.1038/s41591-026-04496-2

DOI: 10.1038/s41591-026-04496-2

Data Access Statement: Due to the need to maintain participant confidentiality for this ongoing longitudinal cohort study, and to ensure compliance with varying restrictions across the multiple territories in which participants were recruited, individual participant-level data cannot be placed in the public domain. Qualified researchers may submit requests for deidentified participant data to the corresponding authors, together with a description of the specific data requested, the proposed analyses and the dissemination plan. Requests will be reviewed by the corresponding authors and supported where possible within the necessary legal framework.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
EFPIA
European Union’s Horizon 2020 research and innovation programme
Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under Grant Agreement 777377

Share